Revelation Biosciences reports $9.1M cash as Q3 '26 net loss expands
Revelation Biosciences reported a wider net loss in Q3 2026 to $3.3 million despite reducing operating cash burn. The company asserts its cash runway will extend into Q2 2027 and announced plans to select a CRO for a new Gemini study.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed